kendallhealthcares.com

Mail: kendallhealthcare@gmail.com (24×7 Support for Franchise Partners)

Phone No.:  +91 9412276419, +91 9258052012, +91 9319974453

Mail: kendallhealthcare@gmail.com (24×7 Support for Franchise Partners)

WOFORCE-250 Tablet

  • Each tablet contains Cefuroxime I.P. 250 mg

  • Broad-spectrum second-generation cephalosporin antibiotic

  • Effective against a wide range of Gram-positive and Gram-negative bacteria

  • Indicated for respiratory tract, urinary tract, skin, and soft tissue infections

  • Ensures fast recovery with strong bacterial coverage

  • Pack size: 10×10 tablets

Category:

WOFORCE-250 Tablet contains Cefuroxime I.P. 250 mg, a broad-spectrum second-generation cephalosporin antibiotic that provides powerful protection against bacterial infections. It works by inhibiting bacterial cell wall synthesis, leading to the destruction of harmful bacteria responsible for various infections.

WOFORCE-250 is effective in treating respiratory tract infections, urinary tract infections, skin infections, ear infections, sinusitis, and soft tissue infections. It ensures fast relief and prevents recurrence when used as prescribed.

This antibiotic offers excellent tissue penetration, high safety, and a proven clinical profile, making it a trusted choice among healthcare professionals for managing bacterial infections.


Key Features & Benefits

  • Provides broad-spectrum antibacterial protection

  • Helps treat respiratory, urinary, and skin infections effectively

  • Clinically proven second-generation cephalosporin

  • Ensures rapid symptom relief and infection control

  • Safe and effective when taken under medical supervision


How to Use

Take the WOFORCE-250 Tablet as prescribed by your physician. It can be taken with or without food, usually every 12 hours, depending on the type and severity of infection. Complete the full course even if symptoms improve early.

Reviews

There are no reviews yet.

Be the first to review “WOFORCE-250 Tablet”

Your email address will not be published. Required fields are marked *

Scroll to Top